AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.

AMCP will release Version 4.1 of the AMCP Format for Formulary Submissions in December 2019. Here's what you can expect.

AMCP webinar that provided insights around the evolution of the pre-approval information exchange between manufacturers and payers.

AMCP webinar that reviewed the current pre-approval support features within FormuarlyDecisions.com and insights from the active FormularyDecisions.com Payer community.

AMCP webinar that discussed the current state of payer perceptions regarding dossier timing, quality and use as well as future considerations for improving dossier relevancy and optimization of use.

AMCP webinar that reviewed the shifting landscape and the need for credible insights to getting the proper information to inform better decisions.

AMCP webinar that reviewed research and evidence that can support the opportunity to use the AMCP eDossier System as a potential safe harbor mechanism.